SCANPatient

SCANPatient


The SCANPatient Study is a randomised clinical trial (RCT), which will compare the standard radiological approach to an alternative standard approach ​for reporting CT scans of the pancreas. This alternative is a standardised synoptic report, to determine if this approach results in a more accurate diagnosis of localised Pancreas Ductal Adenocarcinoma (PC) to improve delivery of care.

Specifically, this novel RCT will determine the role of implementing the synoptic report template embedded into routine care, to assess whether this approach increases institutional accuracy in defining surgical resectability (or operability) of non-metastatic PC.

The diagnostic algorithm incorporated into the synoptic template design will provide a uniform assessment of tumour operability, based on the recently published, international consensus criteria regarding tumour resectability.

Participating Sites


Eligibility
Australian hospitals reviewing and treating an average of at least 20 new patients with pancreatic cancer annually (including patients who present with metastatic disease) will qualify to participate in this RCT.

Recruitment & Randomisation
SCANPatient aims to recruit 40 hospitals across Australia. Randomisation will occur in clusters of eight hospitals which will be randomised to use the synoptic report at six monthly intervals from commencement of the trial.

SCANPatient is seeking expressions of interest (EOI) from interested centres Australia-wide who wish to hear more and potentially join this study. Please complete the SCANPatient EOI Form.

HYPOTHESIS


That the introduction of a synoptic, (structured) radiological template report (which includes an inherent diagnostic algorithm derived from the international consensus guidelines for borderline pancreatic cancer) will alter the rate of diagnosis of borderline (BR) PC from baseline.

STUDY DESIGN


SCANPatient is a stepped wedge RCT. Five clusters of eight hospitals at each randomisation point will switch to the synoptic report, with other hospitals continuing standard of care until randomised to synoptic reporting.

The Pilot


The collaborative pancreatic cancer resectability project, led by SMICS in partnership with NEMICS, was headed by project leads Anna Maciejewska (SMICS) and Nadia Ayres (NEMICS) and clinicians A/Prof Charles Pilgrim, A/Prof Samantha Ellis and Dr Mark Goodwin. The project began in August 2019 and the pilot ran 15 October 2020 – 30 September 2021, trialling a synoptic template for use by radiologists reporting CT scans. The pilot found found the use of a synoptic radiological report for the reporting of pancreatic CT scans demonstrated a clinically significant improvement in the accuracy of assessment of localised pancreatic cancer. The SCANPatient study will formally test this pilot in an RCT nationally from 2022-2027, to determine whether this approach represented an advance that should be adopted more broadly.

CONTACT US


If you would like to know more about SCANPatient, please contact the SCANPatient Coordinating Centre via the form below or via email, SCANPatient@monash.edu

 




Frequently Asked Questions

What is SCANPatient?

The Synoptic reporting of CT scans assessing cancer of the pancreas (SCANPatient) study is a stepped-wedge randomised clinical trial, which will compare the usual standard radiological approach used in most centres around Australia to the new synoptic report, to determine if this approach results in a more accurate diagnosis of localised pancreatic cancer.

Why is this project being conducted?

The Pancreatic Cancer Resectability Pilot Project, found the use of a synoptic radiological report, for the reporting of pancreatic CT scans demonstrated a clinically significant improvement in the accuracy of assessment of localised pancreatic cancer.

The SCANPatient Study will formally test this approach nationally from 2022-2027.

 

How can a hospital express interest in participating?

SCANPatient is seeking expressions of interest (EOI) from interested centres Australia-wide who wish to hear more and potentially join this study. Please complete the SCANPatient EOI Form.

How is SCANPatient being funded?

SCANPatient is funded by a Medical Research Future Fund (MRFF) Rare Cancers, Rare Diseases and Unmet Need Grant.

Who is coordinating SCANPatient?

SCANPatient is led by the Coordinating Principal Investigator A/Prof Charles Pilgrim.

The SCANPatient Coordinating Centre is part of the Cancer Research Program (CRP) within the School of Public Health and Preventive Medicine at Monash University.

The development and operation of SCANPatient will be overseen by a Trial Management Committee and Trial Operations Sub-Committee.

Who are the grant investigators?

  • Chief Investigators
    • A/Prof Charles Pilgrim
    • A/Prof Samantha Ellis
    • A/Prof David Cavallucci
    • Dr Mark D Goodwin
    • Prof Neil Merrett
    • Dr Jessica Yang
    • Dr Lorraine Chantrill
    • Prof John Zalcberg
    • Dr Liane Ioannou
    • A/Prof Jessica Kasza